Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Dmn5.0
D-Mannose – Forschung
Hilft wahrscheinlich
43 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
D-Mannose scheint in 8 von 10 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2014–2026 mit einer typischen Studiengröße von 90 Teilnehmenden.
Basierend auf 43 Studien · 3 Meta-Analysen · 19 RCTs · 21,573 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
8geholfen2unklar· 33 weitere ohne bewertete Effektdaten
Nach Outcome
Urinary tract infection
Hilft wahrscheinlich42 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung7 Studien
Women's health
Überwiegend Mechanismus / Beobachtung5 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung5 Studien
In Zahlen
Aus 28 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
50%
über Studien hinweg
Untersuchte Personen
22k
typische Studie: 90 Personen
Stärkste Designs
22
3 gepoolt, 19 randomisiert
Zeigte Nutzen
80%
8/10 Studien
Wie lange Studien liefen
Unter einer Woche
1
1–3 Monate
3
3+ Monate
4
Untersuchte Populationen
Women with recurrent urinary tract infections2
Women with recurrent UTI2
Catheter and non-catheter users1
Older patients with frailty and recurrent UTI1
Aktives Forschungsgebiet
27 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
201420202026
1Meta-Analysen=10,495 · very large study2025
Einfach gesagt: D-mannose, triple therapy, vaccine, probiotics, and cranberry serve as potential nonantibiotic intervention options for clinical UTI prevention.
Han Z et al. · Infection (2025)
Nearly 80% of the RCTs utilized double-blind or triple-blind designs.
D-mannose, triple therapy, vaccine, probiotics, and cranberry serve as potential nonantibiotic intervention options for clinical UTI prevention.
Prophylactic antibiotic use may reduce recurrence in selected patients but carries significant risks, including Clostridioides difficile infection and antimicrobial resistance.
Clinical decision-making should be guided by individualized risk assessment, careful consideration of treatment burden, and regular reassessment of both benefits and harms.
Further research is urgently needed to inform evidence-based prevention strategies for this vulnerable population.
6Urinary tract infection prevention and treatmentSystematische Übersichtn=598 · large study2022
Einfach gesagt: This comprehensive Cochrane review provides the highest level of evidence synthesis for D-mannose's effectiveness in UTI prevention and treatment.
Domenici L et al. · Cochrane Database of Systematic Reviews (2022)
D-mannose may be effective for preventing recurrent UTIs compared to placebo
Limited evidence suggests D-mannose may be as effective as antibiotics for UTI prevention
More high-quality studies needed to establish optimal dosing and duration
Einfach gesagt: Additional clinical trials are warranted to validate the therapeutic efficacy and durability of these techniques.
Chen YC et al. · International journal of molecular sciences (2023)
Even without underlying anatomic or functional abnormalities, more than 40% of women experience at least one UTI in their lifetime, of which 30% develop recurrent UTIs (rUTIs) within 6 months.
The adaptive evolution of UPEC has been observed in several aspects, including colonization, attachment, invasion, and intracellular replication to invade the urothelium and survive intracellularly.
Combination therapies targeting multiple pathogenic mechanisms are expected to be a future trend in UTI management, although some of these treatment options have not been well established in terms of their long-term efficacy.
8Urinary tract infection prophylaxis efficacySystematische Übersichtn=24 · very small study2023
Einfach gesagt: For those who are interested in trying these products despite the lack of robust evidence for clinical efficacy, it may be helpful to know that the studies included in this review did not identify any clinically important signs of harm, to the extent that safety data were documented and reported.
Song G et al. · The Senior care pharmacist (2023)
This review captured all studies in previous reviews as well as recent publications.
Conclusions The three supplements reviewed appear not to be strongly supported by clinical data.
For those who are interested in trying these products despite the lack of robust evidence for clinical efficacy, it may be helpful to know that the studies included in this review did not identify any clinically important signs of harm, to the extent that safety data were documented and reported.
9D-mannose effects on urinary tract infectionsÜbersicht2022
Einfach gesagt: Research suggests that supplemented D-mannose could be a promising alternative or complementary remedy especially as a prophylaxis for recurrent UTIs.
Ala-Jaakkola R et al. · Nutrition journal (2022)
When excreted in urine, D-mannose potentially inhibits Escherichia coli, the main causative organism of UTIs, from attaching to urothelium and causing infection.
In this review, we provide an overview of UTIs, E. coli pathogenesis and D-mannose and outline the existing clinical evidence of D-mannose in reducing the risk of UTI and its recurrence.
Furthermore, we discuss the potential effect mechanisms of D-mannose against uropathogenic E.coli.
Einfach gesagt: A combination of these agents might provide the optimal treatment to reduce recurrent UTI, and trials in specific population groups are required.
Sihra N et al. · Nature reviews. Urology (2018)
The growing problem of antimicrobial resistance means that the search for nonantibiotic alternatives for the treatment and prevention of UTI is of critical importance.
Some of the results of trials of these approaches are promising; however, high-level evidence is required before firm recommendations for their use can be made.
A combination of these agents might provide the optimal treatment to reduce recurrent UTI, and trials in specific population groups are required.
12Recurrent urinary tract infection pathogenesis and preventionÜbersicht2020
Einfach gesagt: Urinary tract infections are highly prevalent among women and when they are recurrent they can lead to patient discomfort and high healthcare costs, and they represent one of the most frequent caus...
Pigrau C et al. · Medicina clinica (2020)
Urinary tract infections are highly prevalent among women and when they are recurrent they can lead to patient discomfort and high healthcare costs, and they represent one of the most frequent causes of antibiotic consumption.
Einfach gesagt: The last 20 years of research on non-antibiotic approaches in UTI have not brought conclusive evidence that antibiotic usage can be replaced completely by non-antibiotic options.
Wawrysiuk S et al. · Archives of gynecology and obstetrics (2019)
The last 20 years of research on non-antibiotic approaches in UTI have not brought conclusive evidence that antibiotic usage can be replaced completely by non-antibiotic options.
Hence, antibiotics still remain a gold standard for UTI treatment and prevention.
However, changing the therapeutic strategy by including non-antibiotic measures in the management of UTI could be successful in avoiding antimicrobial resistance at least to some extent.
15Proportion with subsequent clinically suspected UTIRCTn=7,591 · very large study2024
Einfach gesagt: In this randomized clinical trial, daily d-mannose did not reduce the proportion of women with recurrent UTI in primary care who experienced a subsequent clinically suspected UTI. d-Mannose should not be recommended for prophylaxis in this patient group.
Hayward G et al. · JAMA internal medicine (2024)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Could be chance
Of 598 women eligible (mean [range] age, 58 [18-93] years), 303 were randomized to d-mannose (50.7%) and 295 to placebo (49.3%).
Primary outcome data were available for 583 participants (97.5%).
The proportion contacting ambulatory care with a clinically suspected UTI was 150 of 294 (51.0%) in the d-mannose group and 161 of 289 (55.7%) in the placebo group (risk difference, -5%; 95% CI, -13% to 3%; P = .26).
Einfach gesagt: Combining fosfomycin and an integrated D-mannose supplement for managing rUTIs offers a potential reduction in antibiotic reliance.
Riemma G et al. · Expert review of anti-infective therapy (2025)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Borderline
Combination therapy had lower number of women matching rUTI criteria (55.32% vs 76.47% and 84%; p < 0.05) and symptoms remission at 12 months (89.36% vs 56.86% and 20%; p < 0.001).
Combining fosfomycin and an integrated D-mannose supplement for managing rUTIs offers a potential reduction in antibiotic reliance.
Further large-scale studies are recommended to confirm these findings.